Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“For the year ended December 31, 2025, one customer accounted for approximately 51% of our total revenues.”
$30M relationship
basisCDXS fy2024 · closed 2024-12 $59M
FILING10-K0001200375-26-000006cik 0001200375
“For the years ended December 31, 2025 and 2024, customers that each individually contributed 10% or more of our total revenue accounted for 51% of our total revenues.”
$30M relationship
basisCDXS fy2024 · closed 2024-12 $59M
FILING
“The increase was primarily due to $34.0 million higher revenue from our licensing agreements with Merck entered into during the second and fourth quarters of 2025, and $3.3 million higher revenue from existing and legacy collaboration agreements.”
FILING10-K0001200375-26-000006cik 0001200375
“This increase was partially offset by the non-recurrence of $6.0 million revenue from our licensing agreement with Roche Sequencing Solutions, Inc. ("Roche") entered into in February 2024, and $9.5 million of revenue related to a license agreement with Pfizer Inc. ("Pfizer") entered into in December 2024.”
FILING10-K0001200375-26-000006cik 0001200375
“To date, we have entered into platform technology licensing agreements with each of GlaxoSmithKline Intellectual Property Development Limited, a subsidiary of GlaxoSmithKline plc ("GSK"), Merck & Co., Inc. ("Merck & Co") and Novartis Pharma AG ("Novartis").”
FILING10-K0001200375-26-000006cik 0001200375
“To date, we have entered into platform technology licensing agreements with each of GlaxoSmithKline Intellectual Property Development Limited, a subsidiary of GlaxoSmithKline plc ("GSK"), Merck & Co., Inc. ("Merck & Co") and Novartis Pharma AG ("Novartis").”
FILING10-K0001200375-26-000006cik 0001200375
“Manufacturing of our enzymes is conducted primarily in four locations: at our in-house facility in Redwood City, California and at third-party contract manufacturing organizations ("CMOs") : Lactosan GmbH & Co. KG ("Lactosan") in Kapfenberg, Austria, ACS Dobfar S.p.A. ("ACSD") (formerly known as DPhar S.p.A.) in Anagni, Italy, and Sekisui Diagnostics (UK) Ltd. ("Sekisui") in Maidstone, United Kingdom.”
FILING10-K0001200375-26-000006cik 0001200375
“Manufacturing of our enzymes is conducted primarily in four locations: at our in-house facility in Redwood City, California and at third-party contract manufacturing organizations ("CMOs") : Lactosan GmbH & Co. KG ("Lactosan") in Kapfenberg, Austria, ACS Dobfar S.p.A. ("ACSD") (formerly known as DPhar S.p.A.) in Anagni, Italy, and Sekisui Diagnostics (UK) Ltd. ("Sekisui") in Maidstone, United Kingdom.”
FILING10-K0001200375-26-000006cik 0001200375
“This increase was partially offset by the non-recurrence of $6.0 million revenue from our licensing agreement with Roche Sequencing Solutions, Inc. ("Roche") entered into in February 2024, and $9.5 million of revenue related to a license agreement with Pfizer Inc. ("Pfizer") entered into in December 2024.”
FILING10-K0001200375-26-000006cik 0001200375
“In December 2023, we entered into an exclusive licensing agreement with Aldevron LLC ("Aldevron"), a global leader in the custom development and manufacture of plasmid DNA, RNA and proteins for the biotech industry, whereby Aldevron licensed our Codex HiCap RNA Polymerase.”
FILING10-K0001200375-26-000006cik 0001200375
“The most advanced of our biotherapeutics programs was CDX-7108, a potent lipase intended for use as a potential treatment for exocrine pancreatic insufficiency ("EPI"), which was being developed under a Strategic Collaboration Agreement with Nestlé Health Science ("Nestlé") (the "Nestlé SCA").”
FILING10-K0001200375-26-000006cik 0001200375
“In March 2023, we entered into a Master Collaboration Agreement and Research Agreement with seqWell (the "seqWell Agreement"), pursuant to which we provided research and experimental screening and enzyme engineering activities in exchange for compensation in the form of additional shares of seqWell's common stock.”
FILING10-K0001200375-26-000006cik 0001200375
“We manufacture our enzymes primarily in four locations: our in-house facility in Redwood City, California, and at three third-party contract manufacturing organizations ("CMOs"): Lactosan in Kapfenberg, Austria, ACS Dobfar S.p.A. ("ACSD") (formerly known as DPhar S.p.A.) in Anagni, Italy, and Sekisui Diagnostics in Maidstone, United Kingdom.”
FILING10-K0001200375-26-000006cik 0001200375
“On May 2, 2024, we entered into a Controlled Equity Offering Sales℠ Agreement (the "Cantor Sales Agreement") with Cantor Fitzgerald & Co., as sales agent ("Cantor"), under which Cantor, at our discretion and at such times that we may determine from time to time, may sell up to a maximum of $75.0 million of shares of our common stock.”
FILING10-K0001200375-26-000006cik 0001200375
“On February 13, 2024, we entered into a five-year term loan and security agreement (the "Loan Agreement") with Innovatus Life Sciences Lending Fund I, LP ("Innovatus"), an affiliate of Innovatus Capital Partners, LLC, as Lender, consisting of up to two tranches, of which the first tranche of $30.0 million was disbursed upon execution of the Loan Agreement and the second tranche of $10.0 million was funded on June 27, 2025 upon achievement of certain financial milestones.”
FILING10-K0001200375-26-000006cik 0001200375
“In May 2021, we entered into an Equity Distribution Agreement ("EDA") with Piper Sandler & Co. ("PSC"), under which PSC, as our exclusive agent, at our discretion and at such times that we determined from time to time, may have sold over a three-year period from the execution of the EDA up to a maximum of $50.0 million of shares of our common stock.”
FILING10-K0001200375-26-000006cik 0001200375
“We manufacture our enzymes primarily in four locations: our in-house facility in Redwood City, California, and at three third-party contract manufacturing organizations ("CMOs"): Lactosan in Kapfenberg, Austria, ACS Dobfar S.p.A. ("ACSD") (formerly known as DPhar S.p.A.) in Anagni, Italy, and Sekisui Diagnostics in Maidstone, United Kingdom.”
FILING10-K0001200375-26-000006cik 0001200375
“In September 2024, we entered into a new non-exclusive commercial and manufacturing license agreement with Alphazyme LLC ("Alphazyme").”
FILING10-K0001200375-26-000006cik 0001200375
“In July 2024, we entered into an asset purchase agreement with Crosswalk Therapeutics ("Crosswalk") for our investigational Fabry and Pompe disease compounds, both of which were previously part of our collaboration agreement with Takeda.”
FILING10-K0001200375-26-000006cik 0001200375
“In January 2025, MAI assigned the MAI Supply Agreement to Maravai in connection with the sale of its related assets to Maravai.”
FILING10-K0001200375-26-000006cik 0001200375
Watchlist prices, news filtered to it, and its next report on your desk.
Prev close 1.39 · gapped above the open, never looked back. High/low 1.49 at 9:30 am ET, 1.39 at 3:45 pm ET.
Codexis, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Industrial Organic Chemicals
Codexis, Inc. has 7 disclosed suppliers and 13 disclosed customers. Each one is named in an SEC filing, either Codexis, Inc.’s own annual report or the counterparty’s, and carries the sentence that discloses it.
CDXS (Codexis, Inc.) has 7 disclosed suppliers and 13 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: MRVI −0.15%, in healthcare.